Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

459 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer.
Uchida T, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y, Hashimoto K, Nishihara F, Murayama Y, Kobayashi K, Kagamu H. Uchida T, et al. Among authors: kaira k. Thorac Cancer. 2019 Apr;10(4):975-979. doi: 10.1111/1759-7714.13039. Epub 2019 Mar 12. Thorac Cancer. 2019. PMID: 30864291 Free PMC article.
[Lung cancer].
Ayabe E, Kaira K, Yamamoto N. Ayabe E, et al. Among authors: kaira k. Gan To Kagaku Ryoho. 2009 Jan;36(1):21-5. Gan To Kagaku Ryoho. 2009. PMID: 19151561 Japanese.
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Masuda T, Imai H, Kuwako T, Miura Y, Yoshino R, Kaira K, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M. Masuda T, et al. Among authors: kaira k. Clin Transl Oncol. 2015 Sep;17(9):702-9. doi: 10.1007/s12094-015-1297-8. Epub 2015 May 20. Clin Transl Oncol. 2015. PMID: 25990507
First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Kuwako T, Imai H, Masuda T, Miura Y, Seki K, Yoshino R, Kaira K, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M. Kuwako T, et al. Among authors: kaira k. Cancer Chemother Pharmacol. 2015 Oct;76(4):761-9. doi: 10.1007/s00280-015-2841-5. Epub 2015 Aug 8. Cancer Chemother Pharmacol. 2015. PMID: 26254024
Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer.
Kaira K, Tomizawa Y, Imai H, Sakurai R, Matsuura M, Yoshii A, Ochiai M, Kotake M, Ebara T, Saitoh JI, Sunaga N, Minato K, Saito R, Hisada T. Kaira K, et al. Cancer Chemother Pharmacol. 2017 Jan;79(1):165-171. doi: 10.1007/s00280-016-3217-1. Epub 2016 Dec 19. Cancer Chemother Pharmacol. 2017. PMID: 27995307 Clinical Trial.
Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.
Imai H, Kuwako T, Kaira K, Masuda T, Miura Y, Seki K, Sakurai R, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M. Imai H, et al. Among authors: kaira k. Cancer Chemother Pharmacol. 2017 Mar;79(3):497-505. doi: 10.1007/s00280-016-3232-2. Epub 2017 Feb 6. Cancer Chemother Pharmacol. 2017. PMID: 28168310 Free PMC article.
459 results